Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes

Sponsor

RenJi Hospital (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05534854

Collaborator

Ruijin Hospital (Other), Shanghai Zhongshan Hospital (Other), Huashan Hospital (Other), Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (Other), Zhejiang Provincial People's Hospital (Other), Tongji Hospital (Other), Second Affiliated Hospital, School of Medicine, Zhejiang University (Other), Shanghai 10th People's Hospital (Other), First Affiliated Hospital, Sun Yat-Sen University (Other), Peking University First Hospital (Other)

500

Enrollment

Location

33.5

Anticipated Duration (Months)

14.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study will investigate the frequency, clinical phenotype, management and molecular genetic defects of heritable kidney cancer syndromes. Families with kidney cancer with known or suspected genetic basis will be enrolled. Affected individuals or individuals suspected of having a germline kidney cancer will undergo periodic clinical assessment and genetic analyses for the purpose of: 1) definition and characterization of phenotype, 2) determination of the natural history of the disorder, and 3) genotype/phenotype correlation. Genetic linkage studies may be performed in situations in which the genetic basis of the disorder has not been elucidated. This research will have a significant impact on the overall management of heritable kidney cancer syndromes patients and family members who are at risk for heritable kidney cancer syndromes. The study will ultimately facilitate the development of novel screening, prevention and treatment strategies for these individuals with the syndrome. In addition this study could have impact on the management of patients with personal and/or family history of heritable kidney cancer syndromes.

Condition or Disease	Intervention/Treatment	Phase
Renal Tumor Histology Kidney Cancer Renal Cell Carcinoma Familial Renal Cancer HLRCC VHL Syndrome BAP1 Tumor Predisposition Syndrome FLCN Gene Mutation ALK Gene Mutation FH Gene Mutation Birt-Hogg-Dube Syndrome MET Gene Mutation Cutaneous Leiomyoma Cutaneous Leiomyomata With Uterine Leiomyomata	Genetic: Gene test

Detailed Description

Background:

• The genetic etiology of heritable kidney cancer syndromes remains to be determined.

Objectives:

Define the risk of developing renal cance in heritable kidney cancer syndromes
Define the types and characteristics (including patterns of growth) of heritable kidney cancer syndromes.
Determine genotype/phenotype correlations.
To characterize the natural and clinical histories of heritable kidney cancer syndromes.
To determine the genetic etiology of heritable kidney cancer syndromes.

Design:

These rare families will be recruited to genetically confirm diagnosis, determine size and location of renal tumors, size at presentation, growth rate and metastatic potential of renal tumors.
Genetic testing will be offered to gain appreciation of the effect of mutations on the relative activity of various germline and somatic mutations.
To determine if there is a relationship between mutation and disease manifestations and phenotype.

Study Design

Study Type:

Observational

Anticipated Enrollment :

500 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes

Anticipated Study Start Date :

Oct 16, 2022

Anticipated Primary Completion Date :

Aug 1, 2025

Anticipated Study Completion Date :

Aug 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Patient with heritable kidney cancer syndrome Patients with known or suspected heritable kidney cancer syndromes, including VHL and HLRCC Disease.	Genetic: Gene test Next generation sequencing of blood, urine and/or benign and malignant tissue of patients and family members with known or suspected heritable kidney cancer syndromes, including VHL and HLRCC Disease.
Family members of heritable kidney cancer syndrome Family members (related by blood) of patients who have or are suspected of having heritable kidney cancer syndromes, including VHL and HLRCC Disease.	Genetic: Gene test Next generation sequencing of blood, urine and/or benign and malignant tissue of patients and family members with known or suspected heritable kidney cancer syndromes, including VHL and HLRCC Disease.
Not proven genetic etiology Patients and biologic family members with a heritable kidney cancer syndrome of suspected, but not proven genetic etiology.	Genetic: Gene test Next generation sequencing of blood, urine and/or benign and malignant tissue of patients and family members with known or suspected heritable kidney cancer syndromes, including VHL and HLRCC Disease.

Arm

Intervention/Treatment

Patient with heritable kidney cancer syndrome

Patients with known or suspected heritable kidney cancer syndromes, including VHL and HLRCC Disease.

Genetic: Gene test

Next generation sequencing of blood, urine and/or benign and malignant tissue of patients and family members with known or suspected heritable kidney cancer syndromes, including VHL and HLRCC Disease.

Family members of heritable kidney cancer syndrome

Family members (related by blood) of patients who have or are suspected of having heritable kidney cancer syndromes, including VHL and HLRCC Disease.

Genetic: Gene test

Not proven genetic etiology

Patients and biologic family members with a heritable kidney cancer syndrome of suspected, but not proven genetic etiology.

Genetic: Gene test

Outcome Measures

Primary Outcome Measures

Clinical phenotypes of patients of heritable kidney cancer syndromes [5 years]
Chart review of disease outcome
Genotypes of patients of heritable kidney cancer syndromes [5 years]
Genotyping for genetic variants that could modify the risk of cancer in subjects.

Secondary Outcome Measures

Clinical phenotypes of family members of the patients [5 years]
Questionnaire and chart review of the clinical phenotype
Prevalence of germline variants in the unselected general population of renal cancer patients [5 years]
Frequency of germline pathogenic/likely pathogenic variants in renal cancer

Eligibility Criteria

Criteria

Ages Eligible for Study:

2 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Participants must be greater than or equal to 2 years of age. All patients and guardians (for children younger than 18 years of age) must sign an informed consent document indicating their understanding of the investigational nature and the risks of this study before any protocol related studies are performed. Patients under the age of 18 but who are age 13 or older will be asked to sign an assent document prior to participation.
Individuals and biologic family members with a suspected or an established diagnosis of a heritable kidney cancer syndrome in which the disease gene is known, including von Hippel-Lindau (VHL) and hereditary papillary renal carcinoma (HPRC).
Individuals and biologic family members with a suspected or an established diagnosis of a heritable kidney cancer syndrome in which the disease gene is not yet known, specifically hereditary forms of Type II papillary renal cancer, clear cell renal carcinoma, renal oncocytoma, chromophobe renal carcinoma or Birt Hogg Dube.
Individuals and biologic family members who have heritable kidney cancer syndromes of suspected, but not proven genetic etiology, including families with more than one individual affected by the same or related cancers.
Subject Enrollment Categories (to include both affected and unaffected biologic relatives).